| Author | Buonora, Sibelle | |
| Author | Nogueira, Susie | |
| Author | Pone, Marcus Vinicius | |
| Author | Aloé, Marisa | |
| Author | Oliveira, Ricardo Hugo | |
| Author | Hofer, Cristina | |
| Access date | 2012-12-04T16:41:38Z | |
| Available date | 2012-12-04T16:41:38Z | |
| Document date | 2008 | |
| Citation | BUONORA, Sibelle et al. Growth parameters in HIV-vertically-infected adolescents on antiretroviral therapy in Rio de Janeiro, Brazil. Annals of Tropical Paediatrics, London, v. 28, n. 1, p. 59-64, 2008. | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/5920 | |
| Description | We would like to express our gratitude for
help given by the Coordenac¸a˜o de
Aperfeic¸oamento de Pessoal de Nı´vel
Superior and Infectious Diseases Post-
Graduation Program, Universidade Federal
do Rio de Janeiro. We would also like to
thank Dr Guilherme Santoro-Lopes for
important suggestions about the manuscript
and Mrs Andrea Fiorani for correcting
the English. | pt_BR |
| Language | eng | pt_BR |
| Publisher | Butterworths Scientific | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | de Martino M, Tovo P-A, Balducci M, et al.
Reduction in mortality with availability of therapy
for children with perinatal HIV-1 infection. JAMA
2000; 284:190–7. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | Mahoney EM, Donfield SM, Howard C,
Kaufman F, Gertner JM. HIV-associated immune
dysfunction and delayed pubertal development in a
cohort of young hemophiliacs. Hemophilia Growth
and Development Study. J Acquir Immune Defic
Syndr 1999; 21:333–7. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | Matarazzo P, Palomba E, Lala R, et al. Growth
impairment, IGF I hyposecretion and thyroid
dysfunction in children with perinatal HIV-1 infection.
Acta Paediatr 1994; 83:1029–34. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | Berhane R, Bagenda D, Marum L, et al. Growth
failure as a prognostic indicator of mortality in
pediatric HIV infection. Pediatrics 1997; 100:e7. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | Laue L, Pizzo PA, Butler K, Cutler GB. Growth
and neuroendocrine dysfunction in children with
acquired immunodeficiency syndrome. J Pediatr
1990; 117:541–5. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | van Rossum AMC, Gaakeer MI, Verweel G, et al.
Endocrinologic and immunologic factors associated
with recovery of growth in children with human
immunodeficiency vı´rus type 1 infection treated
with protease inhibitors. Pediatr Infect Dis J 2003;
22:70–6. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | Arpadi SM, Cuff PA, Kotler DP, et al. Growth
velocity, fat-free mass and energy intake are inversly
related to viral load in HIV-infected children. J Nutr
2000; 130:2498–502. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | McKinney RE Jr, Wilfert C. Growth as a prognostic
indicator in children with human immunodeficiency
virus infection treated with zidovudine: AIDS
Clinical Trials Group Protocol 043 Study Group.
J Pediatr 1994; 125 (5 pt 1):728–33. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | Newell ML, Borja MC, Peckham C. European
Collaborative Study. Height, weight and growth in
children born to mothers with HIV-1 infection in
Europe. Pediatrics 2003; 111:e52–60. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | http://aidsinfo.nih.gov/guidelines/pediatric/PED_032405.
pdf | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | Centers for Disease Control and Prevention.
Revised classification system for human immunodeficiency
virus infection in children less than 13
years of age. MMWR 1994; 43 (RR-12):1–10. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | http://www.bcb.gov.br/?TXDOLAR. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | Nachman SA, Lindsey JC, Moye J, et al. For the
Pediatric AIDS Clinical Trials Group 377 Study
Team. Growth of human immunodeficiency
virus-infected children receiving highly active antiretroviral
therapy. Pediatr Infect Dis J 2005; 24:352–
7. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | Verweel G, van Rossum AMC, Hartwig NG, et al.
Treatment with highly active antiretroviral therapy
in immunodeficiency virus type 1-infected children
is associated with a sustained effect on growth.
Pediatrics 2002; 109:1–7. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | Miller TL, Mawn BE, Orav EJ, et al. The effect of
protease inhibitor therapy on growth and body
composition in human immunodeficiency virus type
1-infected children. Pediatrics 2001; 107:e77. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | Dreimane D, Nielsen K, Deveiks A, Bryson YJ,
Geffner ME. Effect of protease inhibitors combined
with standard therapy on linear growth and weight
gain in human immunodeficiency virus type 1-
infected children. Pediatr Infect Dis J 2001; 20:315–
16. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | Nachman SA, Lindsey JC, Pelton S, et al.
Growth in human immunodeficiency virus-infected
children receiving ritonavir-containing antiretroviral
therapy. Arch Pediatr Adolesc Med 2002; 156:497–
503. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | Guillen S, Ramos JT, Resino R, Bellon JM,
Munoz MA. Impact on weight and height with
the use of HAART in HIV-infected children.
Pediatr Infect Dis J 2007; 26:334–8. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | Junqueira do Lago M, Faerstein E, de Souza
Lopes C, Werneck GL. Pro-Saude Study (Rio de
Janeiro, Brazil). Family socio-economic background
modified secular trends in age at menarche:
evidence from the Pro-Saude Study (Rio de
Janeiro, Brazil). Ann Hum Biol 2003; 30:347–52. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | Buchacz K, Rogol AD, Lindsey JC, et al. Pediatric
AIDS Clinical Trials Group 219 Study Team.
Delayed onset of pubertal development in children
and adolescents with perinatally acquired HIV
infection. J Acquir Immune Defic Syndr 2003;
33:56–65. | pt_BR |
| xmlui.metadata.dc.relation.isbasedon | de Martino M, Tovo PA, Galli L, et al. Puberty in
perinatal HIV-1 infection: a multicentre longitudinal
study of 212 children. AIDS 2001; 15:1527–34. | pt_BR |
| Rights | restricted access | |
| Title | Growth parameters in HIV-vertically-infected adolescents on antiretroviral therapy in Rio de Janeiro, Brazil | pt_BR |
| Type | Article | |
| DOI | 10.1179/146532808X270699 | |
| Abstract | Background: Growth failure in HIV-infected children is an important factor in either initiating or changing
antiretroviral therapy (ART). This study assesses the impact of HIV infection on growth parameters of adolescents
who acquired HIV vertically.
Methods: This retrospective, longitudinal study involved adolescents aged 10–20 years with vertically-acquired HIV
infection who were followed up in one of the three main referral centres for paediatric HIV/AIDS in Rio de Janeiro,
Brazil. Length, weight and variables related to demographic, clinical and laboratory issues were analysed.
Results: 108 subjects were enrolled. Median age was 12.7 years, median duration of follow-up was 97.2 months and
61 (56.5%) were female. The difference between the baseline and final weight Z-scores was 20.31 (p50.02).
Patients with final weight Z-scores (22 used more ART regimens (average 4.13) than those with Z-scores .22
(average 2.90, p,0.01) and also had a lower final CD4z cell percentage — average 19% vs 24% (p,0.01),
respectively. The difference between baseline and final-height Z-scores was 20.27 (p,0.01). Several factors were
associated with a final-height Z-score (22: clinical stage C during follow-up (RR 1.60, 95% CI 1.11–2.31),
chronic diarrhoea during follow-up (RR 2.02, 95% CI 1.04–3.90), HAART use (RR 1.41, 95% CI 1.16–1.71),
number of ART regimens (p,0.01) and final CD4z cell percentage (p,0.01). In multivariate analysis,
presentation in clinical stage C during follow-up was the only significant variable (OR 4.04, 95% CI 1.23–13.28).
Conclusion: Even on HAART, HIV-infected adolescents have lower growth parameters than the normal population
and this is associated with a worse prognosis. | pt_BR |
| Affilliation | Universidade Federal do Rio de Janeiro. Departamento de Medicina Preventiva. Serviço de Doenças Infecciosa. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Departamento de Pediatria. Rio de Janeiro, RJ, Brasil | pt_BR |
| Affilliation | Universidade Federal do Rio de Janeiro. Departamento de Medicina Preventiva. Serviço de Doenças Infecciosa. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Departamento de Pediatria. Rio de Janeiro, RJ, Brasil | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Fernandes Figueira. Departamento de Pediatria. Rio de Janeiro, RJ, Brasil | pt_BR |
| Affilliation | Hospital Municipal Jesus. Departamento de Pediatria. Rio de Janeiro, RJ, Brasil | pt_BR |
| Affilliation | Universidade Federal do Rio de Janeiro. Departamento de Medicina Preventiva. Serviço de Doenças Infecciosa. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Departamento de Pediatria. Rio de Janeiro, RJ, Brasil | pt_BR |
| Affilliation | Universidade Federal do Rio de Janeiro. Departamento de Medicina Preventiva. Serviço de Doenças Infecciosa. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Departamento de Pediatria. Rio de Janeiro, RJ, Brasil | pt_BR |
| DeCS | HIV | pt_BR |
| DeCS | Adolescente | pt_BR |
| DeCS | Terapia Anti-Retroviral de Alta Atividade | pt_BR |
